XLV Tops Quant Ratings as Healthcare ETF Inflows Surge

The Health Care Select Sector SPDR Fund (XLV) has taken the top spot in Quant ratings among healthcare ETFs, a ranking that comes as the sector draws its heaviest inflows in months. Investors are rotating into healthcare for its perceived defense, a shift that shows up in fund flows and positioning data alike.

XLV's Quant score – a composite of valuation, growth, profitability, momentum, and earnings revisions – has climbed as the ETF's underlying components report stable earnings and the broader market faces renewed uncertainty around tariffs and Fed policy. The sector's forward P/E sits below its five-year average, a relative discount that looks attractive when growth stocks are repricing.

The fund flows confirm the rotation. Healthcare ETFs absorbed roughly $2.8 billion in the past four weeks, according to data from FactSet, the highest pace among major sector funds. Much of that money went into XLV and its low-cost peers, suggesting institutional allocators are adding defensive exposure without chasing single-name risk.

For traders, the readthrough is not uniform across healthcare. The inflows are concentrated in large-cap pharma and managed care, where cash flows are predictable and patent cliffs are well-telegraphed. Companies like UnitedHealth Group, Johnson & Johnson, and Pfizer – which together account for more than a third of XLV's weight – benefit directly from the demand for stable cash generation. Biotech, by contrast, has seen more selective buying. The SPDR S&P Biotech ETF (XBI) is up but still below its 200-day moving average, reflecting a market that prices in rate sensitivity more than defensive gravity.

What would confirm the thesis is continued relative outperformance during the next equity drawdown. If XLV can hold its recent gains while the S&P 500 dips, the sector's defensive premium will have real support. A break below XLV's $140 level – its 50-day moving average – would signal that the rotation is more tactical than structural. For now, the data points toward a regime where healthcare serves as a portfolio ballast, not a growth story.